SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma to sell 100% shares in Sun Pharma Japan Technical Operations

01 Jan 2025 Evaluate

Sun Pharmaceutical Industries has entered into an agreement with Zaza Industrial Holdings K.K, Japan, under which Sun Pharma has agreed to sell 100% shares held in Sun Pharma Japan Technical Operations, a step-down subsidiary of the Company (through its subsidiary, Sun Pharma Japan). Consequently, Sun Pharma Japan Technical Operations shall cease to be a subsidiary of the Company. The said transaction is expected to be completed by January 31, 2025. 

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1866.25 -1.55 (-0.08%)
24-Jun-2026 11:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1866.25
Dr. Reddys Labs. 1333.90
Cipla 1429.65
Zydus Lifesciences 1106.70
Lupin 2374.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: